breast cancer - International Pharmaceutical Industry

News

Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals

A widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most co...

8 December 2021 News breast cancer | Canadian Cancer Trials Group

Continue Reading →

News

Late cancer diagnoses rise as NHS struggles with COVID-19

Analyses provided by UK cancer charity Macmillan has provided insights into the repercussions experienced by patients waiting to receive treatment during the COVID-1...

1 December 2021 News breast cancer | cancer

Continue Reading →

News

NICE does not recommend tucatinib for advanced breast cancer

NICE has published draft guidance for public consultation which does not recommend tucatinib, in combination with trastuzumab and capecitabine, for some types of bre...

27 October 2021 News breast cancer | capecitabine

Continue Reading →

News

UK trial to evaluate existing drugs for secondary breast cancer

A new UK-based clinical trial will evaluate existing cancer drugs as potential treatments for women living with metastatic breast cancer. The study, led by Profes...

29 September 2021 News Bavencio | breast cancer

Continue Reading →

News

Roche withdraws US approval for Tecentriq in mTNBC

Roche has voluntarily withdrawn its US accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy for the treatment of adults with unresectab...

1 September 2021 News antibody | atezolizumab

Continue Reading →

News

Enhertu improves progression-free survival in breast cancer trial

Positive topline results from a Phase III trial for Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu have shown that the HER2-directed antibody drug conju...

11 August 2021 News AstraZeneca | breast cancer

Continue Reading →